5-Fluorouracil: mechanisms of action and clinical strategies

Daniel B Longley; D Paul Harkin; Patrick G Johnston

doi:10.1038/nrc1074

5-Fluorouracil: mechanisms of action and clinical strategies

Daniel B Longley, D Paul Harkin, Patrick G Johnston

Research output: Contribution to journal › Article › peer-review

3049 Citations (Scopus)

Abstract

5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.

Original language	English
Pages (from-to)	330-338
Number of pages	9
Journal	Nature Reviews. Cancer
Volume	3
DOIs	https://doi.org/10.1038/nrc1074
Publication status	Published - May 2003

Keywords

Animals
Antimetabolites, Antineoplastic
Biological Markers
Dihydrouracil Dehydrogenase (NADP)
Fluorouracil
Humans
Interferons
Microsatellite Repeats
Oligonucleotide Array Sequence Analysis
Oxidoreductases
RNA
Thymidine Phosphorylase
Thymidylate Synthase
Tumor Suppressor Protein p53

ASJC Scopus subject areas

Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nrc1074

Cite this

@article{64dfe824a0814451bc12094c1cc5d4c0,

title = "5-Fluorouracil: mechanisms of action and clinical strategies",

abstract = "5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.",

keywords = "Animals, Antimetabolites, Antineoplastic, Biological Markers, Dihydrouracil Dehydrogenase (NADP), Fluorouracil, Humans, Interferons, Microsatellite Repeats, Oligonucleotide Array Sequence Analysis, Oxidoreductases, RNA, Thymidine Phosphorylase, Thymidylate Synthase, Tumor Suppressor Protein p53",

author = "Longley, {Daniel B} and Harkin, {D Paul} and Johnston, {Patrick G}",

year = "2003",

month = may,

doi = "10.1038/nrc1074",

language = "English",

volume = "3",

pages = "330--338",

journal = "Nature Reviews. Cancer",

issn = "1474-175X",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - 5-Fluorouracil: mechanisms of action and clinical strategies

AU - Longley, Daniel B

AU - Harkin, D Paul

AU - Johnston, Patrick G

PY - 2003/5

Y1 - 2003/5

N2 - 5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.

AB - 5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.

KW - Animals

KW - Antimetabolites, Antineoplastic

KW - Biological Markers

KW - Dihydrouracil Dehydrogenase (NADP)

KW - Fluorouracil

KW - Humans

KW - Interferons

KW - Microsatellite Repeats

KW - Oligonucleotide Array Sequence Analysis

KW - Oxidoreductases

KW - RNA

KW - Thymidine Phosphorylase

KW - Thymidylate Synthase

KW - Tumor Suppressor Protein p53

UR - http://www.scopus.com/inward/record.url?scp=0038387494&partnerID=8YFLogxK

U2 - 10.1038/nrc1074

DO - 10.1038/nrc1074

M3 - Article

C2 - 12724731

VL - 3

SP - 330

EP - 338

JO - Nature Reviews. Cancer

JF - Nature Reviews. Cancer

SN - 1474-175X

ER -

5-Fluorouracil: mechanisms of action and clinical strategies

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this